HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf S&E

This article was originally published in The Rose Sheet

Executive Summary

Consumer divisions in North America performed particularly well in the first quarter, with Beiersdorf recording sales growth of 8.5% and La Prairie sales gaining 43%, German consumer products manufacturer says in a May 14 1report. "Dramatic developments" in exchange rates in the Americas, however, led to a 17.7% drop in sales year-on-year, the company noted. Global sales of the Cosmed division increased 1% at current exchange rates to $912.9 mil. (€1=$1.15) with growth of Nivea offset by negative currency impact. Earnings before interest and taxes for the division were flat at $125.3 mil. Consolidated sales at constant exchange rates rose 7.4% in Q1, while sales at current exchange rates were flat at $1.37 bil. Earnings before interest and taxes were flat at $152.9 mil...

You may also be interested in...



Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel